Related references
Note: Only part of the references are listed.Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer
Kartik Sehgal et al.
CLINICAL LUNG CANCER (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection
QuanQiu Wang et al.
JAMA ONCOLOGY (2021)
Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
Vanita Noronha et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis
Nikolaj Frost et al.
CLINICAL LUNG CANCER (2020)
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study
Lennard Y. W. Lee et al.
LANCET (2020)
Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study
Kunyu Yang et al.
LANCET ONCOLOGY (2020)
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19
Daniel A. Goldstein et al.
JAMA ONCOLOGY (2020)
Chemotherapy and COVID-19 Outcomes in Patients With Cancer
Justin Jee et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study
S. Visser et al.
EUROPEAN JOURNAL OF CANCER (2019)
Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer
Roberto Ferrara et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review
K. S. Versteeg et al.
ANNALS OF ONCOLOGY (2014)
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Jean-Louis Pujol et al.
CLINICAL LUNG CANCER (2014)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Translocation A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Jeong-Ok Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer
Yuichiro Ohe et al.
CLINICAL CANCER RESEARCH (2008)
Share Paper
